Abstract 1750: Design and development of a novel highly sequence-selective guanine mono-alkylating DNA-interactive ADC payload suitable for solid tumor treatments

Autor: Paolo Andriollo, George Procopiou, Daniella M. di Mascio, Paul J. Jackson, Khondaker M. Rahman, Keith R. Fox, David E. Thurston

Publikováno v: Cancer Research. 82:1750-1750

Antibody-Drug Conjugates (ADCs) are a fast-growing class of targeted cancer therapeutic agents with over ten approved and greater than 100 in various stages of clinical development. The pyridinobenzodiazepines (PDDs) are a new class of DNA-interactiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfc419ab528626ba06c439f4adfb8d96
https://doi.org/10.1158/1538-7445.am2022-1750

Abstract 6334: In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for the treatment of solid tumors

Autor: Paul J. Jackson, Paolo Andriollo, Nicolas Veillard, George Procopiou, David E. Thurston

Publikováno v: Cancer Research. 82:6334-6334

Antibody-Drug Conjugates (ADCs) are a growing class of therapeutic agents for the treatment of cancer, with thirteen approved and over 100 others in clinical development. The pyridinobenzodiazepine (PDD) platform is a toolbox of sequence-selective, D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95b23ea7b1a855499a260b6128981402
https://doi.org/10.1158/1538-7445.am2022-6334

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma

Autor: Silvia Crescioli, Anthony Cheung, Paul J. M. Jackson, Silvia Mele, Katie E. Lacy, David E. Thurston, Paolo Andriollo, James Spicer, Ricarda M. Hoffmann, Connie Kin Fun Chui, Eirini Sachouli, Sophia N. Karagiannis

Publikováno v: Hoffmann, R M, Crescioli, S, Mele, S, Sachouli, E, Cheung, A, Chui, C, Andriollo, P, Jackson, P J M, Lacy, K E, Spicer, J, Thurston, D & Karagiannis, S N 2020, ' A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma ', Cancers . https://doi.org/10.3390/cancers12041029
Cancers
Cancers, Vol 12, Iss 1029, p 1029 (2020)
Hoffmann, R M, Crescioli, S, Mele, S, Sachouli, E, Cheung, A, Chui, C K, Andriollo, P, Jackson, P J M, Lacy, K E, Spicer, J F, Thurston, D E & Karagiannis, S N 2020, ' A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma ', Cancers, vol. 12, no. 4, 1029 . https://doi.org/10.3390/cancers12041029
Volume 12
Issue 4

Despite emerging targeted and immunotherapy treatments, no monoclonal antibodies or antibody-drug conjugates (ADCs) directly targeting tumor cells are currently approved for melanoma therapy. The tumor-associated antigen chondroitin sulphate proteogl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4760505805f28ffa009ddc03da0f646
https://doi.org/10.3390/cancers12041029

C8-Linked Pyrrolobenzodiazepine Monomers with Inverted Building Blocks Show Selective Activity against Multidrug Resistant Gram-Positive Bacteria

Autor: Paolo, Andriollo, Charlotte K, Hind, Pietro, Picconi, Kazi S, Nahar, Shirin, Jamshidi, Amrit, Varsha, Melanie, Clifford, J Mark, Sutton, Khondaker Miraz, Rahman

Publikováno v: ACS infectious diseases. 4(2)

Antimicrobial resistance has become a major global concern. Development of novel antimicrobial agents for the treatment of infections caused by multidrug resistant (MDR) pathogens is an urgent priority. Pyrrolobenzodiazepines (PBDs) are a promising c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aeddff21a5e991747276b2eee7b2764a
https://pubmed.ncbi.nlm.nih.gov/29260545

Abstract 736: Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity

Autor: Paul J. M. Jackson, Julia Mantaj, Patricia A. Cooper, Schopperle William Michael, Yawen Ju, K Miraz Rahman, Keith R. Fox, David E. Thurston, Steven D. Shnyder, George Procopiou, Francesco Cascio, Paolo Andriollo, David B. Corcoran, Nicolas Veillard, Ilona Pysz, Tan Edwin Saavedra

Publikováno v: ResearcherID

Although four ADCs have been approved and over sixty others are in development, the majority contain payloads belonging to two classes; tubulin inhibitors and DNA cross-linkers. Challenges in the development of ADCs include managing off-target toxici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae2e1b2233a9595209e66a02327c8f4
https://doi.org/10.1158/1538-7445.am2018-736